CARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cara Therapeutics's enterprise value is $-53.65 Mil. Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-117.65 Mil. Therefore, Cara Therapeutics's EV-to-EBITDA for today is 0.46.
The historical rank and industry rank for Cara Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Cara Therapeutics was 887.81. The lowest was -163.65. And the median was -5.25.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-14), Cara Therapeutics's stock price is $0.7236. Cara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.190. Therefore, Cara Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Cara Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -5.40 | 103.49 | -5.53 | -5.10 | 0.46 |
Cara Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -5.10 | -1.79 | -0.53 | -0.17 | 0.46 |
For the Biotechnology subindustry, Cara Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's EV-to-EBITDA falls into.
Cara Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -53.653 | / | -117.65 | |
= | 0.46 |
Cara Therapeutics's current Enterprise Value is $-53.65 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-117.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cara Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.7236 | / | -2.190 | |
= | At Loss |
Cara Therapeutics's share price for today is $0.7236.
Cara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Cara Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Posner | director | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Helen M Boudreau | director | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Joana Goncalves | officer: Chief Medical Officer | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Scott Terrillion | officer: Sec'y; Chief Compliance & G.C. | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Menzaghi Frederique Ph.d. | officer: VP-Research & Development | C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484 |
Moltke Lisa Von | director | C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
Martin Vogelbaum | director | 675 ALMANOR AVE, SUNNYVALE CA 94085 |
Ryan D Maynard | officer: Chief Financial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Csl Ltd | 10 percent owner | |
Jeffrey L. Ives | director | C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484 |
Bains Harrison M Jr | director | |
Thomas Charles Reilly | officer: Chief Financial Officer | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Vifor Fresenius Medical Care Renal Pharma Ltd. | 10 percent owner | RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014 |
Vifor (international) Ltd | 10 percent owner | RECHENSTRASSE 37, ST. GALLEN V8 9000 |
Vifor Pharma Ltd. | 10 percent owner | UNTERMATTWEG 8, BERNE V8 CH-3027 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-28-2022
By Value_Insider Value_Insider • 11-02-2022
By sperokesalga sperokesalga • 02-21-2023
By Stock market mentor Stock market mentor • 01-03-2023
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 11-03-2022
By Marketwired • 09-25-2023
By Value_Insider Value_Insider • 10-24-2022
By Marketwired • 09-05-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.